D. Camidge

发表

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

A. Shaw, R. Doebele, D. Proia, 2013, Cancer discovery.

Clinical Investigation : Thoracic Cancer Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

R. Doebele, L. Gaspar, B. Kavanagh, 2014 .

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

R. Doebele, E. Berge, D. Camidge, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treating ALK-positive lung cancer—early successes and future challenges

R. Doebele, D. Camidge, D. Ross Camidge, 2012, Nature Reviews Clinical Oncology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

D. Camidge, L. Chow, S. Leong, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

N. Pavlakis, A. Shaw, T. Mok, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiotherapy.

B. Kavanagh, D. Camidge, S. Nath, 2019, International journal of radiation oncology, biology, physics.

Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

E. Collisson, F. Kaye, I. Yeh, 2019, Clinical Cancer Research.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

D. Camidge, D. Camidge, 2008 .

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

R. Doebele, D. Camidge, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer

Erin L. Schenk, R. Doebele, D. Camidge, 2019, Front. Oncol..

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Radiosurgery for Small-Cell Brain Metastases: Challenging the Last Bastion of Preferential Whole-Brain Radiotherapy Delivery.

P. Brown, D. Camidge, C. Rusthoven, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

G. Giaccone, P. Jänne, F. Khuri, 2014, Cancer.

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.

F. Hirsch, P. Bunn, W. Franklin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.

Erin L. Schenk, P. Bunn, R. Doebele, 2019, Clinical lung cancer.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

P. Bunn, R. Doebele, L. Gaspar, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

D. Camidge, S. Shreeve, H. Burris, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

J. Lee, D. Gomez, J. Welsh, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

F. Cappuzzo, M. Varella‐Garcia, R. Doebele, 2012, Clinical Cancer Research.

The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence

D. Camidge, Andrew J. Weickhardt, D. Ross Camidge, 2011 .

Pharmacodynamic Studies in Early Phase Drug Development

A. Jimeno, R. Doebele, D. Camidge, 2011 .

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

M. Varella‐Garcia, B. Solomon, D. Camidge, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2012 .

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

P. Bunn, R. Doebele, D. Camidge, 2010, Lung cancer.

Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).

A. Iafrate, M. Socinski, S. Ou, 2014 .

Targeting ALK in inflammatory myofibroblastic tumours.

D. Camidge, V. Villalobos, D. Camidge, 2018, The Lancet. Respiratory medicine.

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .

Update to Rociletinib Data with the RECIST Confirmed Response Rate.

L. Sequist, J. Soria, D. Camidge, 2016, The New England journal of medicine.

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.

M. von Mehren, D. Camidge, L. Chow, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Jie Yang, S. Gettinger, M. Ahn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.

M. Hidalgo, L. Sequist, F. Ringeisen, 2014 .

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).

A. Drilon, S. Ou, A. Shaw, 2019, Journal of Clinical Oncology.

Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis

B. Kavanagh, M. Stares, D. Camidge, 2009, Acta oncologica.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

T. Clackson, A. Shaw, S. Gettinger, 2013 .

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

J. Engelman, A. Shaw, E. Felip, 2013 .

The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers.

F. Hirsch, R. Dziadziuszko, D. Camidge, 2009, Clinical lung cancer.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

A. Drilon, A. Shaw, S. Ou, 2018, Cancer discovery.

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience.

W. Franklin, M. Varella‐Garcia, R. Doebele, 2016, Archives of pathology & laboratory medicine.

Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study

J. Lee, D. Gomez, S. Swisher, 2016, The Lancet. Oncology.

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

M. Varella‐Garcia, D. Aisner, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

K. Kerr, R. Doebele, D. Camidge, 2019, Nature Reviews Clinical Oncology.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

H. Groen, W. Pao, E. Smit, 2017, Lung cancer.

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

A. Atherly, D. Camidge, A. Atherly, 2012, British Journal of Cancer.

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

N. Rosenfeld, R. Govindan, V. Plagnol, 2019, JCO precision oncology.

Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + non-small cell lung cancer.

R. Doebele, D. Gerber, T. Stinchcombe, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CSF cytology identifies mechanisms of tyrosine kinase inhibitor resistance in patient with EGFR-mutated NSCLC with CNS progression

D. Aisner, Sudabeh Balakhani, D. Camidge, 2023, Clinical Lung Cancer.

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

Acquired resistance to TKIs in solid tumours: learning from lung cancer

W. Pao, L. Sequist, D. Camidge, 2014, Nature Reviews Clinical Oncology.

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.

P. Bunn, R. Doebele, D. Aisner, 2016, Lung cancer.

Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer

D. Aisner, D. Camidge, T. Jiang, 2018, Cancer.

Molecular origins of lung cancer: prospects for personalized prevention and therapy.

Kwok-Kin Wong, R. Herbst, D. Carbone, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.

R. Doebele, B. Solomon, A. Baron, 2013, Clinical lung cancer.

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

S. Ou, M. Varella‐Garcia, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Jeffrey W. Clark, A. Iafrate, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing.

J. Minna, J. Shay, D. Camidge, 2010, The Journal of clinical investigation.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

S. Gettinger, A. Amini, B. Kavanagh, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Finding ALK-positive lung cancer: what are we really looking for?

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Erin L. Schenk, T. Burns, D. Camidge, 2020 .

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

P. Ascierto, P. Ott, M. Hellmann, 2017 .

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

Susan M. Chang, P. Brown, M. Mehta, 2013, The Lancet. Oncology.

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development

D. Camidge, A. Hughes, D. Johnstone, 2005, British Journal of Cancer.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

C. Rudin, J. Nemunaitis, B. Halmos, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeted manipulation of apoptosis in cancer treatment.

D. Camidge, J. Call, S. Eckhardt, 2008, The Lancet. Oncology.

Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.

D. Camidge, Elaine M. Jennings, S.M. Gadgeel, 2023, Clinical lung cancer.

Updates in the management of brain metastases.

Eudocia Q Lee, Brian M Alexander, Riccardo Soffietti, 2016, Neuro-oncology.

Reviewing RECIST in the Era of Prolonged and Targeted Therapy.

D. Camidge, Rustain L. Morgan, D. Camidge, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

G. Demetri, S. Gwyther, M. Leach, 2013, Clinical Cancer Research.

Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Drilon, S. Ou, 2017 .

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.

D. Camidge, A. Weickhardt, Eiko Theodora Browning, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer

Kenneth L. Jones, P. Bunn, M. Varella‐Garcia, 2018, Clinical Cancer Research.

Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013, PloS one.

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.

D. Gao, D. Camidge, J. Pacheco, 2019, Annals of translational medicine.

Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients.

W. Franklin, M. Varella‐Garcia, R. Doebele, 2012 .

The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes.

D. Webb, D. Camidge, D. Jodrell, 2008, British journal of clinical pharmacology.

Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

J. von Pawel, D. Camidge, D. Spigel, 2014, Clinical lung cancer.

Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).

R. Heist, E. Felip, A. Navarro, 2020 .

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Jeffrey W. Clark, S. Ou, S. Ou, 2018 .

Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.

A. Shaw, S. Ou, T. Mok, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer.

K. Venkatakrishnan, D. Camidge, N. Narasimhan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management strategies for early onset pulmonary events associated with brigatinib.

N. Rizvi, D. Camidge, L. Bazhenova, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

L. Sequist, J. Schellens, P. LoRusso, 2014 .